JW Pharmaceutical Completes Phase 3 Dosing for Gout Drug Epaminurad in Multi-Country Asian Trial
核心洞察
JW Pharmaceutical (搜索) has completed final patient dosing in its Phase 3 clinical trial of epaminurad (URC102), an oral gout treatment candidate, with the last patient dosed in Malaysia on April 23.
The multinational trial evaluated epaminurad's uric acid-lowering efficacy and safety compared to febuxostat across five Asian countries including Korea, Taiwan, Thailand, Malaysia, and Singapore.
Epaminurad works as a selective inhibitor of hURAT1 (搜索), a renal uric acid transporter, addressing unmet medical needs in gout treatment where existing therapies face safety limitations.
JW Pharmaceutical (搜索) announced Thursday the completion of final patient dosing in its Phase 3 clinical trial for epaminurad (URC102), an investigational oral treatment for gout and hyperuricemia. The last patient was dosed in Malaysia on April 23, marking a significant milestone for the Korean pharmaceutical company's lead gout therapy candidate.
Novel Mechanism Targets Uric Acid Excretion
Epaminurad represents a new approach to gout treatment, functioning as a uric acid excretion promoter that selectively inhibits hURAT1 (搜索), a renal uric acid transporter. Gout is a metabolic disease characterized by abnormally high uric acid levels in the blood, where uric acid produced in the body is not properly excreted and accumulates, depositing in cartilage, tissues around joints, and subcutaneous tissue, causing inflammation and pain.
The Phase 3 trial was designed to evaluate the blood uric acid-lowering efficacy and safety of epaminurad compared with febuxostat, an existing treatment. The multinational study was conducted across five Asian countries: Korea, Taiwan, Thailand, Malaysia, and Singapore, following approval of the Phase 3 investigational new drug (IND) application from Korea's Ministry of Food and Drug Safety in 2022.
Addressing Unmet Medical Needs
According to JW Pharmaceutical (搜索), existing gout treatments that promote uric acid excretion in under-excretor gout patients have faced prescription limitations due to safety concerns regarding the kidneys and liver. The company developed epaminurad specifically to address this unmet medical need in the gout treatment landscape.
In the previous Phase 2 clinical trial, epaminurad met both primary and secondary efficacy endpoints, with confirmed safety and tolerability profiles. During the Phase 3 trial, the U.S. Data Safety Monitoring Board (DSMB) recommended continuing the trial as planned at multiple meetings, indicating favorable safety signals.
Patent Protection and Global Strategy
JW Pharmaceutical (搜索) recently strengthened its intellectual property position by registering a use patent for epaminurad with the United States Patent and Trademark Office (USPTO). This patent registration extends the drug's exclusivity period in the U.S. market from 2029 to 2038, providing nearly a decade of additional market protection.
The patent portfolio has been registered in 18 countries, including Korea, the United States, Canada, and Australia. Reviews are currently underway in 11 additional countries, including those in Europe, Japan, and China, suggesting a comprehensive global commercialization strategy.
Timeline for Results
JW Pharmaceutical (搜索) plans to complete follow-up observations and data compilation with the goal of producing a results report by the end of this year. "With the completion of dosing for the last patient in the Phase 3 trial of epaminurad, we will focus our capabilities on follow-up observations, data compilation, and detailed analysis with the goal of producing a results report by year-end," a JW Pharmaceutical official stated.
The company emphasized its commitment to developing epaminurad as a new treatment option that can address unmet medical needs in the field of gout treatment, potentially offering patients an alternative to existing therapies with improved safety profiles.